Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Citigroup Inc.

Citigroup Inc. reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,987 shares of the medical equipment provider’s stock after selling 21,898 shares during the period. Citigroup Inc.’s holdings in Zimmer Biomet were worth $16,839,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. bought a new stake in Zimmer Biomet during the second quarter worth approximately $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Zimmer Biomet in the second quarter worth approximately $43,000. Finally, Ridgewood Investments LLC bought a new position in shares of Zimmer Biomet in the second quarter valued at $43,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.3 %

ZBH opened at $112.06 on Thursday. The company has a market capitalization of $22.31 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The business has a 50-day moving average of $107.07 and a 200-day moving average of $109.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the firm earned $1.65 earnings per share. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. UBS Group decreased their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Oppenheimer reduced their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. BTIG Research cut their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.